Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 3/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5512399 | 0.81 | FABP4 (0.45) | SMN1; SMN2MAPTNFKB1HDAC4HDAC1 | |
| SCHEMBL5512368 | 0.79 | FABP4 (0.46) | CNR2SMN1; SMN2MAPTHDAC4HDAC1 | |
| SCHEMBL28345767 | 0.75 | FABP4 (0.45) | SMN1; SMN2MAPTHDAC4HDAC1HDAC7 | |
| SCHEMBL23853379 | 0.73 | CNR2 (0.39) | CNR2SMN1; SMN2MAPTHPGDKDM4E | |
| SCHEMBL8807589 | 0.73 | RECQL (0.67) | SMN1; SMN2RAB9AMAPTNPC1HDAC4 | |
| SCHEMBL7924316 | 0.72 | CNR2 (0.62) | CNR2CNR1 | |
| SCHEMBL23850522 | 0.71 | MEN1 (0.45) | CNR2SMN1; SMN2RAB9AMAPTNPC1 | |
| SCHEMBL312344 | 0.71 | HDAC4 (0.77) | MAPTHDAC4HDAC1HDAC7HDAC11 | |
| SCHEMBL1064861 | 0.71 | HDAC4 (0.77) | MAPTHDAC4HDAC1HDAC7HDAC11 | |
| SCHEMBL9852009 | 0.71 | BRD4 (0.44) | CNR2CNR1SMN1; SMN2RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-H11509230-A | — | — | 1999-08-17 | — | — | JP | claimed |
| US-8974823-B2 | Solid compositions of low-solubility drugs and poloxamers | BEND RESEARCH, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| CN-101981005-A | Atorvastatin-aliskiren | LEK PHARMACEUTICALS | 2011-02-23 | — | — | CN | disclosed |
| US-20080318218-A1 | Compositions and Methods for Inferring an Adverse Effect in Response to a Drug Treatment | DNAPRINT GENOMICS, INC. | 2008-12-25 | — | — | US | disclosed |
| WO-2008089557-A1 | ATORVASTATIN CALCIUM PROPYLENE GLYCOL SOLVATES | APOTEX PHARMACHEM INC. (CA) | 2008-07-31 | — | — | WO | disclosed |
| EP-1815023-A2 | COMPOSITIONS AND METHODS FOR INFERRING AN ADVERSE EFFECT IN RESPONSE TO A DRUG TREATMENT | DNAprint Genomics, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20070141143-A1 | Solid compositions of low-solubility drugs and poloxamers | PFIZER PRODUCTS INC. | 2007-06-21 | — | — | US | disclosed |
| WO-2006053322-A2 | COMPOSITIONS AND METHODS FOR INFERRING AN ADVERSE EFFECT IN RESPONSE TO A DRUG TREATMENT | DNAPRINT GENOMICS, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| EP-1373202-B1 | PREPARATION OF NON-CRYSTALLINE ATORVASTATIN CALCIUM | LEK TOVARNA FARMACEVTSKIH (SI) | 2005-04-27 | — | — | EP | disclosed |
| EP-1150665-A2 | USE OF STATINS FOR TREATING VIRAL INFECTIONS | Hollis-Eden Pharmaceuticals Inc. (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000047196-A2 | USE OF STATINS FOR TREATING VIRAL INFECTIONS | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |